|
First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Novartis, GSK, Nanocarrier, NorthWest Biotherapeutics, Roche/Genentech, BergPharma, Bayer, Incyte, FujiFilm, Pharmamar, D3, Pfizer Amgen, Abbvie, Multivir, Bluprint Medicines. |
Travel, Accommodations, Expenses - Novartis, Pharmamar, Fujifilm |
|
|
Honoraria - Celgene; Lilly; Merrimack |
Consulting or Advisory Role - Celgene; Merrimack |
Research Funding - Abbvie; Bayer; Celgene; Genentech/Roche; Lilly; Millennium |
|
|
Employment - D3 Oncology Solutions |
Travel, Accommodations, Expenses - D3 Oncology Solutions |
|
|
Employment - D3 Oncology Solutions |
|
|
Employment - D3 Oncology Solutions |
|
|
Employment - D3 Oncology Solutions |
|
|
No Relationships to Disclose |
|
|
Employment - D3 Oncology Solutions |
|
|
Employment - D3 Oncology Solutions |
|
|
Employment - D3 Oncology Solutions |
|
|
Employment - D3 Oncology Solutions |
|
|
Employment - D3 Oncology Solutions |
|
|
Employment - Experimental Therapeutics Centre |
|
|
Employment - Experimental Therapeutics Centre |
|
|
Employment - Duke-National University of Singapore (NUS) Medical School, Singapore |
|
|
Employment - Duke-National University of Singapore (NUS) Medical School, Singapore |
|
|
Employment - A STAR Singapore; Experimental Therapeutics Centre |